Skip to main content
. 2019 Aug 19;1(3):otz026. doi: 10.1093/crocol/otz026

FIGURE 1.

FIGURE 1.

(A) Pre-infliximab plasma OSM concentrations (pg/mL) was evaluated between biochemical responders (>50% reduction in baseline fecal calprotectin) and nonresponders with the Mann–Whitney test (data are log-transformed). (B) Receiver-operating characteristic analysis was then performed to identify the pre-infliximab OSM cut point (Youden index) that was associated with biochemical nonresponse.